AstraZeneca plc (LON:AZN) had its price target boosted by Deutsche Bank AG from GBX 5,350 ($67.68) to GBX 5,700 ($72.11) in a report published on Monday, May 15th. They currently have a buy rating on the biopharmaceutical company’s stock.
Several other research analysts also recently commented on AZN. Shore Capital restated a sell rating on shares of AstraZeneca plc in a report on Sunday, April 2nd. HSBC Holdings plc cut their price target on AstraZeneca plc from GBX 4,700 ($59.46) to GBX 4,500 ($56.93) and set a hold rating on the stock in a report on Tuesday, February 7th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($49.34) price target on AstraZeneca plc and gave the company a sell rating in a report on Thursday, May 11th. Bryan, Garnier & Co reiterated a buy rating and issued a GBX 5,400 ($68.31) price target on shares of AstraZeneca plc in a report on Tuesday, February 28th. Finally, Berenberg Bank cut their price target on AstraZeneca plc from GBX 5,500 ($69.58) to GBX 5,450 ($68.94) and set a buy rating on the stock in a report on Tuesday, February 21st. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of GBX 5,121.80 ($64.79).
AstraZeneca plc (AZN) traded up 0.02% during midday trading on Monday, hitting GBX 5284.00. The company had a trading volume of 3,878,930 shares. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The company’s market capitalization is GBX 66.90 billion. The stock has a 50 day moving average price of GBX 5,087.18 and a 200 day moving average price of GBX 4,684.86.
WARNING: This article was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/06/16/deutsche-bank-ag-increases-astrazeneca-plc-azn-price-target-to-gbx-5700-updated-updated-updated.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.